Apellis Pharmaceuticals, Inc.

As of March 31, 2026, Apellis Pharmaceuticals, Inc. has 127.92M shares outstanding.

As of March 31, 2026, Apellis Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 38.25. The price-to-sales ratio is 4.61, and the price-to-book ratio stands at -1.70.

As of March 31, 2026, Apellis Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 31.02 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.68 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 31.28 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Apellis Pharmaceuticals, Inc. trades at an EV/FCF ratio of 63.75, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of March 31, 2026, Apellis Pharmaceuticals, Inc. maintains a current ratio of 3.63, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 114.66, indicating elevated leverage, while an interest coverage ratio of 3.82 demonstrates adequate ability to service its debt obligations.

These figures cover the twelve months ended March 31, 2026. Return on invested capital (ROIC) comes in at 21.38 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 14.10, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is negative at -6.81, pointing to unprofitable operations over the period. Inventory turnover of 1.01 indicates how many times Apellis Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures cover the twelve months ended March 31, 2026. That works out to an effective tax rate of 1.39, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

As of the close on May 15, 2026, Apellis Pharmaceuticals, Inc.'s stock has gained approximately 150.79% over the past 52 weeks. The 50-day moving average sits at 33.20, while the 200-day moving average is 26.08.

Over the twelve months ended March 31, 2026, Apellis Pharmaceuticals, Inc. posted a gross margin of 90.19, reflecting its pricing power and cost economics. The operating margin of 14.95 and net profit margin of 12.06 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 0.73, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.17, meaning Apellis Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of March 31, 2026, Apellis Pharmaceuticals, Inc. has an Altman Z-Score of 3.06, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.